Cite
HARVARD Citation
Huth, F. et al. (2022). Novel Bruton's Tyrosine Kinase inhibitor remibrutinib: Drug‐drug interaction potential as a victim of CYP3A4 inhibitors based on clinical data and PBPK modeling. Clinical and translational science. 15 (1), pp. 118-129. [Online].